China Fund News reporter Yishan
On the evening of December 22, Weichuang Co., Ltd. and Wohua Pharmaceutical successively announced that they had received the "Notice of Case Filing" issued by the China Securities Regulatory Commission, and that Weichuang Co., Ltd., the proposed acquirer Liu Jun, and Wohua Pharmaceutical were all filed due to suspected violations of information disclosure laws and regulations.
It is worth noting that, according to the self-inspection announcement disclosed by Weichuang shares, Liu Jun, the company's proposed acquirer, has transferred 1.33 billion yuan of the company's funds to the bank account controlled by it through a condominium bank account, and has not yet returned it to the company. In this regard, the Shanghai Stock Exchange quickly issued an "Inquiry Letter", requiring Weichuang to take all necessary means to recover relevant funds and safeguard the interests of the company and small and medium-sized shareholders.
Both the shares of Weitron and the proposed acquirer were filed
On the evening of December 22, Weichuang Co., Ltd. issued two announcements, the company and the company's proposed acquirer Liu Jun received the "Notice of Case Filing" issued by the China Securities Regulatory Commission on the same day, Liu Jun and the company were suspected of illegal information disclosure, and were decided to file a case by the China Securities Regulatory Commission.
Weichuang said that during the investigation, the company will actively cooperate with the investigation of the China Securities Regulatory Commission and fulfill its information disclosure obligations in strict accordance with regulatory requirements. At present, the company's business situation is normal.
Weichuang also issued a self-inspection announcement on the evening of December 22, disclosing a number of previously undisclosed matters and specific contents.
First, after self-examination, on September 20 this year, Jiangsu Sunshine Group Co., Ltd., the controlling shareholder of the company's controlling shareholder Zhongshu Kluwer, the controlling shareholder of Monsas (Taizhou) Investment Co., Ltd., signed the "Equity Transfer Cooperation Framework Agreement" with Xiling Energy, according to the agreement arrangement, Xiling Energy will obtain the control of Zhongshu Wolters Kluwer through investment relations in the next 12 months. Liu Jun, the actual controller of Xiling Energy, the proposed acquirer, transferred 1.33 billion yuan of the company's funds to the bank account controlled by him through a condominium bank account from September 28 to October 27 this year, and returned the company in full on October 31, but since November 1, the company has been transferred out in batches, and the funds have not been returned to the company as of the disclosure date of this announcement.
In this regard, the Shanghai Stock Exchange also quickly issued a "Letter of Inquiry", requiring Weichuang to take all necessary means to recover relevant funds, safeguard the interests of the company and small and medium-sized shareholders, and carefully self-examine and rectify the deficiencies in internal control.
Second, after self-examination, Zhang Shuhan, the current secretary of the board of directors of the company, submitted a resignation report to the board of directors on November 3 this year, and Zhang Wendong, an independent director, submitted a resignation report to the board of directors on November 30 this year. The resignation information of the above two directors and senior executives has not been disclosed as of the disclosure date of this announcement because the company is in the stage of being investigated.
According to the data, Weichuang shares are mainly engaged in video business and child growth platform. In the first three quarters of this year, the company achieved revenue of 363 million yuan, down 15.68% year-on-year, and net profit attributable to the parent company of 13.471 million yuan, down 82.36% year-on-year. As of the end of the reporting period, the total number of shareholders of the company was 41,000.
As of the close of trading on December 22, Weichuang shares were quoted at 4.82 yuan per share, up about 13% during the year, and the latest market value was 4.4 billion yuan.
Wohua Pharmaceutical was filed
On the evening of December 22, Wohua Pharmaceutical announced that the company received the "Notice of Case Filing" issued by the China Securities Regulatory Commission on December 21, and the China Securities Regulatory Commission decided to file a case against the company due to the company's suspected illegal information disclosure, according to the "Securities Law of the People's Republic of China", "Administrative Punishment Law of the People's Republic of China" and other laws and regulations.
Wohua Pharmaceutical said that according to the company's understanding, the relevant matters related to the filing of this case involve the company's recent failure to fulfill its information disclosure obligations in a timely manner. During the investigation period, the company will actively cooperate with the relevant work of the China Securities Regulatory Commission and strictly fulfill the information disclosure obligations in accordance with the regulations. At present, the company's production and operation activities are carried out normally, the business conditions are stable and orderly, and this investigation will not have a significant adverse impact on the company's production, operation and management.
Wind shows that since November, the company has not disclosed many announcements, except for the announcement disclosed on the evening of December 22, the two announcements issued in November are about the company's chairman and actual controller Zhao Bingxian. Among them, Zhao Bingxian was taken into custody in early November, and was lifted from retention in custody by the relevant discipline inspection and supervision organs in the second half of the same month. As for the reason for Zhao Bingxian's detention, Wohua Pharmaceutical did not further disclose, but said that the matters involved had nothing to do with the company.
According to the data, the predecessor of Wohua Pharmaceutical can be traced back to Wanhetang Pharmaceutical in the Qianlong period of the Qing Dynasty, which is a Chinese patent medicine enterprise with a history of more than 200 years, integrating R&D, production and sales. At present, the company has 162 drug approval numbers, including 15 exclusive products.
In the first three quarters of this year, the company achieved revenue of 716 million yuan, down 4.84% year-on-year, and net profit attributable to the parent company of 57.4013 million yuan, down 27.45% year-on-year. As of the end of the period, the total number of shareholders of the company was 40,900.
At the close of trading on December 22, Wohua Pharmaceutical reported 6.35 yuan per share, down 2.31%, and the latest market value was 3.7 billion yuan.
Editor: Captain
Review: Xu Wen